Ramucirumab biosimilar (Klus Pharma)

雷莫芦单抗生物类似药 (Klus Pharma)

Report date: 2025/04/30 14:07:24

Base Information

Drug NameRamucirumab biosimilar (Klus Pharma)
Drug Alias NameA168A-168
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionVascular endothelial growth factor receptor 2 antagonists
TargetsVascular endothelial growth factor receptor 2
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesKlus Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesKlus Pharma Inc
Inactive CompaniesN/A
Active IndicationsN/A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A